Clinical Applications

PuraMatrix® has demonstrated efficacy in multiple models for hemostasis (CE Mark approved, trade name PuraStat®), tissue regeneration, acute myocardial infarction, therapeutic protein and stem cell delivery, and CNS injury. PuraMatrix® can re-hydrate and provide mechanical support for disc height collapse in degenerated IVDs, anti-adhesion, polyp resection, and bone formation. PuraMatrix® has also been used to repair and restore visual function in the CNS after damage.

s-dots_14

Drug Delivery

PuraMatrix® can be combined with many different cell types, biologically-active agents (i.e., platelet rich plasma), proteins (growth factors, cytokines, or antibodies) and siRNA or drugs prior to administration. Specific growth factors alone or in combination with other biologically active agents such as cytokines (epidermal growth factor, nerve growth factor, transforming growth factor-alpha and beta, platelet-derived growth factor, insulin-like growth factor, vascular endothelial growth factor, et al) have been demonstrated to be effective in animal models in combination with PuraMatrix®.

Click here for peer-reviewed publications of PuraMatrix® in Drug Delivery clinical applications.

News

Find out the most recent developments at 3-D Matrix

Learn More

Collaborations

Learn how PuraMatrix® can enhance your technology

Learn More

Publications

Review the strong body of literature utilizing PuraMatrix®

Learn More

This website is not intended for French healthcare professionals.

If you are a French healthcare professional, please contact your sales representative for any information.


Ce site internet n’est pas destiné aux professionnels de santé française.

Si vous êtes un professionnel de santé français, merci de contacter votre contact local pour toutes demandes d’informations.

Continue